The
selective serotonin reuptake inhibitors (
SSRIs) may occasionally induce extrapyramidal side-effects (EPS) and/or
akathisia. This may be a consequence of serotonergically-mediated inhibition of the dopaminergic system. Manifestations of these effects in patients may depend on predisposing factors such as the presence of psychomotor disturbance, a previous history of
drug-induced akathisia and/or EPS, concurrent antidopaminergic and/or serotonergic
therapy, recent
monoamine oxidase inhibitor discontinuation, comorbid
Parkinson's disease and possibly deficient
cytochrome P450 (CYP)
isoenzyme status. There is increasing awareness that there may be a distinct form of melancholic or
endogenous depression with neurobiological underpinnings similar to those of disorders of the basal ganglia such as
Parkinson's disease. Thus, it is not surprising that some individuals with
depressive disorders appear to be susceptible to developing
drug-induced EPS and/or
akathisia. In addition, the propensity for the
SSRIs to induce these effects in individual patients may vary within the
drug class depending, for example, on their selectivity for
serotonin relative to other monoamines, affinity for the
5-HT2C receptor, pharmacokinetic drug interaction potential with concomitantly administered
neuroleptics and potential for accumulation due to a long half-life. The relative risk of EPS and
akathisia associated with
SSRIs have yet to be clearly established. The potential risks may be reduced by avoiding rapid and unnecessary dose titration. Furthermore, early recognition and appropriate management of EPS and/or
akathisia is required to prevent the impact of these effects on patient compliance and subjective well-being. It is important that the rare occurrence of EPS in patients receiving
SSRIs does not preclude their use in
Parkinson's disease where their potentially significant role requires more systematic evaluation.